医药行业周报：原料药供给节奏变化加速

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The supply of raw materials in the pharmaceutical industry is accelerating, with a focus on subsequent price and volume changes [2] - The global GLP-1 market is evolving, with Chinese companies continuing to explore international opportunities [3] - Leading companies are gradually entering the small nucleic acid field, which is expected to drive the development of supporting industrial chains [4] - The retail pharmaceutical market is showing positive trends, with chain pharmacies enhancing their positioning [5] - The value of oral immunosuppressive drugs is gaining attention [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 1.47 percentage points in the last week, ranking 15th among 31 primary industry indices [18] - The pharmaceutical industry index increased by 0.14% during the same period [18] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has a current PE (TTM) of 37.31, above the five-year historical average of 31.11 [40] 3. Recent Research Achievements - The report highlights various deep-dive studies on topics such as the growth of biological agents and oral medications, and the impact of policies on the inhalation drug industry [44] 4. Recent Industry Policies and News - The National Healthcare Security Administration issued a notice to accelerate the cultivation and application of new scenarios in the medical insurance sector [46] - Recent approvals for clinical trials of new drugs by major pharmaceutical companies, including AstraZeneca and Hengrui Medicine, indicate ongoing innovation in the industry [47][48] 5. Key Companies and Profit Forecasts - The report includes profit forecasts for several companies, with recommendations for stocks such as Yuyuan Pharmaceutical and Sunshine Nuohua, indicating a positive outlook for their performance [9]